-
2023-505042-25-00
5
2020-05-05
Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
-
2023-506783-14-00
5
2020-02-24
Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
-
2023-508853-13-00
4
2019-10-31
Oropharyngeal Squamous Cell Carcinoma
-
2024-511849-19-00
4
2019-10-17
Luminal B Breast Cancer
-
2023-507886-25-00
4
2019-09-27
Previously untreated and symptomatic patients with histologically prov
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2024-511850-34-00
9
2019-01-02
Previously untreated locally recurrent inoperable or metastatic triple
-
2024-513206-65-00
5
2018-08-10
resected squamous cell carcinoma of head and neck
-
2022-502798-40-00
5
2017-07-31
Patients with resected colon carcinoma
-
2023-509671-17-00
5
2017-07-12
Breast Cancer
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2024-511096-15-00
5
2014-08-01
Breast Cancer
-
2024-516996-34-00
5
2012-04-12
oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
-
2024-515452-20-00
4
2025-04-01
Narcolepsy Type 2
-
2024-511112-24-00
4
2025-01-17
Narcolepsy Type 1
-
2024-511998-30-00
5
2024-10-18
Narcolepsy with Cataplexy (Narcolepsy Type 1)
-
2023-508445-40-00
4
2024-07-01
Obstructive Sleep Apnea
-
2023-504892-25-00
5
2024-06-14
Narcolepsy
-
2022-502481-24-00
4
2024-05-23
Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)
-
2023-504955-28-01
4
2024-03-14
Sleep disturbances associated with menopause
-
2023-505543-39-00
5
2024-02-12
Chronic Obstructive Pulmonary Disease (COPD)
-
2022-501988-40-00
5
2023-08-17
RSV-associated (subtypes A and B) disease in adults aged 60 years of a
-
2022-501063-41-00
5
2023-04-20
Chronic Obstructive Pulmonary Disease (COPD)
-
2022-502375-37-00
6
2023-04-16
heartburn